PhRMA backs Novartis' stance on punitive damages

10/6/2013 | Forbes

The Supreme Court could decide to review a case involving the question of whether drugmakers should be exempt from punitive damages in state product-liability lawsuits because the penalties overstep the FDA's enforcement powers. The fines that the FDA can levy could be greatly surpassed by punitive-damages awards, which put "enforcement discretion in the hands of tort plaintiffs who act as a private attorney general under the law," according to a brief from the drugmaker. The Pharmaceutical Research and Manufacturers of America has filed a friend-of-the-court brief in support of Novartis.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC